Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
- Published In:
- Clinical pharmacokinetics, 57(12), 1529-1538 (2018)
- Authors:
- Hall, Sylvie, Isaacs, Diana, Clements, Jennifer N(2)
- Database ID:
- RPEP-03694
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03694APA
Hall, Sylvie; Isaacs, Diana; Clements, Jennifer N. (2018). Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.. Clinical pharmacokinetics, 57(12), 1529-1538. https://doi.org/10.1007/s40262-018-0668-z
MLA
Hall, Sylvie, et al. "Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.." Clinical pharmacokinetics, 2018. https://doi.org/10.1007/s40262-018-0668-z
RethinkPeptides
RethinkPeptides Research Database. "Pharmacokinetics and Clinical Implications of Semaglutide: A..." RPEP-03694. Retrieved from https://rethinkpeptides.com/research/hall-2018-pharmacokinetics-and-clinical-implications
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.